Rare HHS Patent Suit May Impact HIV Drug Pricing, Access

By Dani Kass (November 14, 2019, 7:01 PM EST) -- The U.S. Department of Health and Human Services doesn't make a habit of suing for patent infringement.

It may be because the agency has fewer patents than the average research university or drugmaker. Or it may be because it licenses them widely. Either way, the agency rarely gets aggressive enough to sue.

Which is why its Nov. 6 infringement suit against Gilead Sciences Inc. in Delaware federal court caught the intellectual property world off guard, and gave a sense of hope to activists pushing for increased access to the company's landmark HIV prevention drug, Truvada, and the newly approved Descovy....

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.

  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!


Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!